Bayer Aktiengesellschaft (FRA:BAYN)
Germany · Delayed Price · Currency is EUR | Market Cap | 38.58B +75.2% |
| Revenue (ttm) | 45.58B -2.2% |
| Net Income | -3.62B |
| EPS | -3.68 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 9.26 |
| Dividend | 0.11 (0.28%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 853,422 |
| Average Volume | 13,891 |
| Open | 40.94 |
| Previous Close | 39.27 |
| Day's Range | 40.12 - 41.14 |
| 52-Week Range | 19.35 - 49.76 |
| Beta | n/a |
| RSI | 56.79 |
| Earnings Date | May 12, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial StatementsNews
Bayer US head says tariffs will not affect its 2026 forecasts
A top Bayer AG executive said on Tuesday the German drugmaking and crop science company saw no need to adjust its 2026 forecasts because of tariffs on imported pharmaceuticals announced by the U.S. ...
EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing regim...
Bayer Weighs U.S. Pharma Expansion as Turnaround Picks Up Speed
How Bayer Uses AI to Avoid Sending Customers to its Competition
As generative AI and creators take a bigger hand in producing creative work, brand managers face a crucial question: Who’s watching to ensure its all working together to build brand […]
National Advertising Division Recommends Bayer Modify or Discontinue Certain One A Day Men's Pre-Conception Health Complete Multivitamin Claims
Following a challenge brought by OLLY PBC, BBB National Programs' National Advertising Division recommended that Bayer HealthCare LLC discontinue or modify certain claims for its One A Day® Men's Pre-...
Bayer Announces Leadership Change Within Pharmaceuticals' Worldwide Markets Organization in the U.S. to Support Company's Full Growth Potential
Nelson Ambrogio appointed to lead U.S. pharmaceuticals business, Bayer's largest pharmaceutical growth market Appointment supports Bayer Pharmaceuticals' strategy to renew top-line growth and maxi...
Bayer Announces Leadership Change Within Pharmaceuticals' Worldwide Markets Organization in the U.S. to Support Company's Full Growth Potential
BERLIN--(BUSINESS WIRE)--Bayer today announced a leadership change within its Pharmaceuticals' Worldwide Markets organization to accelerate the strong performance and growth of its key pharmaceutical ...
Bayer Announces Approval Of New Indication For Kerendia In The EU
(RTTNews) - Bayer (BYR.L, BAYRY.PK, BAYZF.PK, BAY.MI, BAYN.DE) announced that the European Commission has granted approval in the European Union for Kerendia or finerenone, a selective, non-steroidal ...
EQS-PVR: Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Bayer Aktiengesellschaft Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Euro...
Bayer Crop Science Canada Redefines Canola Innovation With New ‘Advancing Better Canola’ Initiative
Bayer challenges industry to redefine canola innovation and reframe canola’s future around real, lasting systems. CALGARY, Alberta — Bayer Crop Science Canada launches Advancing Better Canola (ABCs), ...
Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative
CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science Canada launches Advancing Better Canola (ABCs), an industry-wide initiative to challenge and redefine how it thinks about canola innovation in sup...
Multiplatinum Rapper, Actor Ludacris Partners with One A Day to Help People Realize that Health Does Not Need to Be Ludacris
One A Day, the multivitamin and supplement brand from Bayer backed by more than 80 years of nutritional science, today announced a partnership with Grammy Award winning recording artist, actor and phi...
Activist investor Inclusive Capital looks to sell stake in Bayer, Bloomberg News reports
Inclusive Capital Partners is looking to sell a stake in German agriculture and health firm Bayer AG , Bloomberg News reported on Monday.
Formycon Secures Europe Launch Timing For FYB203 After Regeneron, Bayer Settlement
(RTTNews) - Formycon AG (FYB.DE, FYBGF), an independent German biotechnology company, on Thursday announced that it entered into a settlement and license agreement with Regeneron Pharmaceuticals, Inc....
EQS-News: Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer ...
Bayer Crop Science Launches 2026 Opportunity Scholarship Program
CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science Canada is excited to support the future of Canadian agriculture with its 2026 Bayer Crop Science Opportunity Scholarship. Through the scholarship,...
Bayer's Finerenone Meets Primary Endpoint In Phase 3 Study For Non-Diabetic Chronic Kidney Disease
(RTTNews) - Bayer AG (BRY.L) announced that its Phase 3 FIND-CKD trial has met its primary endpoint, showing that Finerenone, significantly slowed kidney function decline in adults with non-diabetic c...
EPA chief met with Bayer CEO over supreme court fight, agency records show
Top US regulators met with Bill Anderson to discuss ‘supreme court action’ over glyphosate weed killer Top US regulators met with Bill Anderson, Bayer’s CEO, last year to discuss “litigation” issues –...
Bayer takes its multi-front battle on pesticide liability to Kansas
Kansas lawmakers were set to take up a bill on Tuesday backed by Bayer that would prevent people from suing pesticide manufacturers for not warning them that their products could cause cancer or othe...
Bayer's $7.25 billion Roundup settlement gets initial OK from Missouri judge
A state court judge in Missouri gave an initial green light on Wednesday to a proposed $7.25 billion settlement to resolve thousands of lawsuits claiming Bayer's Roundup weedkiller causes cancer.
New FDA 510(k) Clearance Expands Bayer's MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (...
Bayer Net Loss Widens on Weedkiller Litigation Charges
The agriculture and pharmaceutical company reported a steeper net loss, including a €3.55 billion hit mainly from litigation-related expenses.
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
BERLIN--(BUSINESS WIRE)--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary ef...
Bayer's XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases.
Some roundup plaintiffs seek to delay preliminary approval of proposed $7.25 bln bayer settlement, court filing shows
Law firms representing nearly 20,000 people who sued Bayer over alleged injuries from its Roundup weedkiller urged a Missouri judge on Wednesday to delay reviewing the German company's proposed $7.25 ...